Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Cardiology

Arrhythmic Mitral Valve Prolapse: Navigating High-Risk Markers

At a Glance

Arrhythmic mitral valve prolapse is a less common form of MVP linked to frequent or complex ventricular extra beats. Doctors combine heart-monitor results, imaging findings, and symptoms to guide monitoring and treatment; no single marker predicts danger by itself.

For the vast majority of people with Mitral Valve Prolapse (MVP), the condition is benign. However, a small subset of patients falls into a category called Arrhythmic Mitral Valve Prolapse (AMVP). In these individuals, the structural variation of the valve can trigger electrical disturbances in the heart’s lower chambers (ventricles), regardless of whether the valve is leaking or not [1][2].

Understanding AMVP is not about increasing anxiety, but about precision. By identifying specific physical and electrical “markers,” cardiologists can determine who needs closer monitoring and who can remain on a standard care path [3].

Defining AMVP

AMVP is characterized by the presence of mitral valve prolapse combined with frequent or complex “extra beats” (ventricular arrhythmias) that cannot be explained by any other underlying cause [1].

  • The 5% Threshold: A Premature Ventricular Contraction (PVC) burden of 5% or more on a 24-hour heart monitor is a consensus threshold used by specialists to help identify a higher-risk phenotype [1][2]. It is not a standalone diagnosis; lower burdens can matter with complex rhythms, and higher burdens do not automatically mean you are at imminent risk.
  • Complex Rhythms: AMVP also considers whether patients experience non-sustained ventricular tachycardia (NSVT) or sustained VT. Survival from a sudden cardiac arrest is a major clinical event that requires immediate advanced evaluation [1].

Identifying the Risk Pattern

No single finding predicts a dangerous rhythm for an individual. Instead, doctors look for a “phenotype”—a specific collection of traits that appear more often in patients with rhythm risks [4][5]:

  1. Bileaflet Prolapse: When both the front and back “flaps” of the mitral valve bulge backward, rather than just one [4][5].
  2. Mitral Annular Disjunction (MAD): A physical separation between the base of the valve and the heart muscle. While many people have small versions of this, it is sometimes associated with more frequent extra beats [5][6].
  3. T-Wave Inversions: Specific patterns on a standard EKG (electrocardiogram) in the “inferior” leads (the bottom part of the heart) that suggest the heart’s electrical recovery is being affected [4][7].
  4. Fibrosis (LGE): Using a Cardiac MRI, doctors look for Late Gadolinium Enhancement—microscopic scarring that often forms on the papillary muscles (the “anchors” of the valve) or the back wall of the heart [8][9][10].

(Note: Bileaflet prolapse, MAD, T-wave changes, and LGE are associations and risk markers, not predictions for an individual. Having incidental MAD or bileaflet prolapse carries low absolute risk for most people.)

Diagnostic Tools for AMVP

If your doctor suspects you may have an arrhythmic risk, they will use several tools to map your heart’s electrical activity:

  • Holter Monitor: A wearable device used for 24–48 hours to count your PVC burden, keeping in mind that variable burdens might not be captured in a single day [7][2].
  • Implantable Loop Recorder (ILR): A tiny device placed under the skin that can monitor your heart for years. It is particularly useful if you have infrequent fainting spells that a short-term monitor might miss [6].
  • Exercise Stress Test: Since some arrhythmias are triggered by exertion, an exercise test can reveal rhythm patterns that don’t show up at rest [11][7].

Management and Treatment Options

The management of AMVP involves individualized electrophysiology decisions:

  • Medication: Beta-blockers are often used. They may help symptoms or selected ventricular ectopy, but they are not established as a universal strategy to prevent sudden death for every person with AMVP [12].
  • Catheter Ablation: In this procedure, a specialist uses a thin tube to reach the heart and ablate the tissue triggering the extra beats. This is often very effective at reducing symptoms, though papillary-muscle procedures can be technically difficult, and arrhythmias can recur [13][14].
  • ICD (Implantable Cardioverter Defibrillator): An ICD is reserved for secondary prevention (survivors of sustained VT/VF) or carefully selected high-risk primary prevention cases; it is not recommended merely because a PVC percentage or a single imaging marker is present [15][16].

Identifying these markers early allows your care team to be proactive, helping you manage your risk safely [1][17].

Common questions in this guide

What is arrhythmic mitral valve prolapse?
It is mitral valve prolapse accompanied by frequent or complex abnormal rhythms from the heart’s lower chambers that are not explained by another cause. It can occur whether or not the valve is leaking, and having MVP alone does not mean a person has AMVP.
Does a PVC burden of 5% mean I am in danger?
A PVC burden of 5% or more on a 24-hour monitor is a consensus threshold doctors use to help identify a higher-risk AMVP pattern. It is not a diagnosis or a prediction of imminent danger; complex rhythms can matter at lower burdens, and a higher burden does not automatically mean a dangerous outcome.
Which ECG or imaging findings are linked to higher rhythm risk in MVP?
Doctors may look for prolapse of both mitral leaflets, separation called mitral annular disjunction, inverted T waves in the lower ECG leads, and scar-like tissue seen as late gadolinium enhancement on cardiac MRI. These findings are associations rather than guarantees, and incidental annular separation or bileaflet prolapse has low absolute risk for most people.
What tests can detect heart rhythms that come and go?
A Holter monitor records rhythm for 24 to 48 hours and estimates the number of PVCs, but one day may miss a variable pattern. An exercise test may reveal exertion-related rhythms, while an implantable loop recorder can monitor for years when fainting or other events are infrequent.
Can medication or ablation treat arrhythmic mitral valve prolapse?
Beta-blockers may reduce palpitations or some extra beats, but they have not been established as a universal way to prevent sudden death in AMVP. Catheter ablation can reduce symptoms and the rhythm source, although procedures near the papillary muscles can be technically challenging and rhythms may return.
When might someone with AMVP need an ICD?
An implantable cardioverter-defibrillator is generally considered for secondary prevention after sustained ventricular tachycardia or ventricular fibrillation, or for carefully selected people at high risk who have not had such an event. A PVC percentage or one imaging marker alone is not usually enough to recommend an ICD.

Get notified when new evidence is published on mitral valve prolapse.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Effectiveness of the risk stratification proposed by the 2022 European Heart Rhythm Association Expert Consensus statement on arrhythmic mitral valve prolapse.

    L'Hoyes W, Robyns T, Moura-Fereira S, et al.

    American heart journal 2023; (266()):48-60 doi:10.1016/j.ahj.2023.08.004.

    PMID: 37595658
  2. 2

    Multiparametric Approach to Arrhythmic Mitral Valve Prolapse: Novel and Recognized Markers of Increased Sudden Cardiac Arrest Risk.

    Jaworski K, Kowalik I, Firek B, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2026; (39(1)):1-14 doi:10.1016/j.echo.2025.07.011.

    PMID: 40749988
  3. 3

    Prevalence, Genetics, and Imaging Characteristics of Patients with Mitral Valve Prolapse and Arrhythmogenic Right Ventricular Cardiomyopathy.

    Rich A, Tastet L, Cristin L, et al.

    medRxiv : the preprint server for health sciences 2026; doi:10.64898/2026.05.14.26353246.

    PMID: 42238433
  4. 4

    High-risk phenotypes of arrhythmic mitral valve prolapse: a systematic review and meta-analysis.

    Benjanuwattra J, Kewcharoen J, Phinyo P, et al.

    Acta cardiologica 2023; (78(9)):1012-1019 doi:10.1080/00015385.2023.2227487.

    PMID: 37358248
  5. 5

    Arrhythmic risk profile in mitral valve prolapse: A systematic review and metanalysis of 1715 patients.

    Pistelli L, Vetta G, Parlavecchio A, et al.

    Journal of cardiovascular electrophysiology 2024; (35(2)):290-300 doi:10.1111/jce.16149.

    PMID: 38098308
  6. 6

    Ventricular arrhythmias in arrhythmic mitral valve syndrome-a prospective continuous long-term cardiac monitoring study.

    Aabel EW, Chivulescu M, Lie ØH, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2023; (25(2)):506-516 doi:10.1093/europace/euac182.

    PMID: 36256597
  7. 7

    Identifying the High-Risk Arrhythmic Mitral Valve Prolapse Phenotype by Imaging.

    Thamman R, Haugaa KH, Hung J, Delling FN

    JACC. Cardiovascular imaging 2026; doi:10.1016/j.jcmg.2026.07.028.

    PMID: 42867428
  8. 8

    Impact of Myocardial Fibrosis and Female Sex on Life-Threatening Arrhythmias and Sudden Cardiac Death in Mitral Valve Prolapse.

    Darwish A, Nguyen DT, Songsangjinda T, et al.

    Circulation. Cardiovascular imaging 2026; (19(9)):e020017 doi:10.1161/CIRCIMAGING.126.020017.

    PMID: 42549505
  9. 9

    Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death.

    Basso C, Perazzolo Marra M, Rizzo S, et al.

    Circulation 2015; (132(7)):556-66 doi:10.1161/CIRCULATIONAHA.115.016291.

    PMID: 26160859
  10. 10

    The Mitral Annulus Disjunction Arrhythmic Syndrome.

    Dejgaard LA, Skjølsvik ET, Lie ØH, et al.

    Journal of the American College of Cardiology 2018; (72(14)):1600-1609 doi:10.1016/j.jacc.2018.07.070.

    PMID: 30261961
  11. 11

    Ventricular arrhythmias during exercise in patients with mitral valve prolapse.

    van Wijngaarden AL, de Riva M, Sabbag A, et al.

    Heart (British Cardiac Society) 2026; (112(14)):781-788 doi:10.1136/heartjnl-2025-326395.

    PMID: 41115769
  12. 12

    Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs.

    Larson J, Rich L, Deshmukh A, et al.

    Journal of clinical medicine 2022; (11(11)) doi:10.3390/jcm11113233.

    PMID: 35683620
  13. 13

    The Outcome of Ventricular Arrhythmias Associated With Mitral Valve Prolapse After Catheter Ablation: A Systematic Review and Meta-Analysis.

    Wibawa K, Ivan I, Jessica G, Ridjab D

    Cureus 2021; (13(12)):e20310 doi:10.7759/cureus.20310.

    PMID: 35024259
  14. 14

    Arrhythmic mitral valve prolapse in 2023: Evidence-based update.

    Kubala M, Essayagh B, Michelena HI, et al.

    Frontiers in cardiovascular medicine 2023; (10()):1130174 doi:10.3389/fcvm.2023.1130174.

    PMID: 37144062
  15. 15

    Case Report: From multimodality imaging to catheter ablation of ventricular arrhythmias in arrhythmogenic mitral valve prolapse.

    Alzammam A, Alanazi F, Alenazy S, et al.

    Frontiers in physiology 2025; (16()):1654085 doi:10.3389/fphys.2025.1654085.

    PMID: 40917806
  16. 16

    Incidence and type of recurrent ventricular arrhythmia in patients with arrhythmic mitral valve prolapse and implantable cardioverter defibrillator for secondary prevention.

    Kneizeh K, Sacher F, Notaristefano F, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2026; (28(6)) doi:10.1093/europace/euag101.

    PMID: 42138650
  17. 17

    Arrhythmogenic Mitral Valve Prolapse: Can We Risk Stratify and Prevent Sudden Cardiac Death?

    Cameron JN, Kadhim KI, Kamsani SH, et al.

    Arrhythmia & electrophysiology review 2024; (13()):e11 doi:10.15420/aer.2023.26.

    PMID: 39145277

This page is for informational purposes only and does not constitute medical advice. Your cardiologist or electrophysiologist should interpret your rhythm tests and risk markers in the context of your health.

Guide contents mitral valve prolapse
Research & Literature
03 Demystifying Your Imaging 05 Living with MVP